Skip to main content

Table 4 Modulation of MGMT promoter methylation

From: MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy

Patient

Pre-treatment

Post-treatment

 

MGMT

MGMT

CD133

MGMT

MGMT

CD133

 

Promoter

  

Promoter

  

Patient 1

M

+

++

M

+/−

+

Patient 2

M

++

+

U

++

+/−

Patient 3

U

+++

+

U

+

++

Patient 4

M

++

+

M

++

+

Patient 5

M

+

++

U

+

+

Patient 6

U

+

+

M

+

+

Patient 7

U

+

+

U

+

+++

Patient 8

M

+

++

U

+

++

Patient 9

U

+/−

+

-

 

-

Patient 10

U

+/−

+

U

++

++

Patient 11

M

++

+

M

+++

+

  1. MGMT and CD133 in recurrent GBM before and after treatment with radiotherapy and temozolomide.